Natco’s US marketing partner files ANDA for Everolimus Tablets

05 Sep 2014 Evaluate

Natco Pharma’s marketing partner in the USA, Breckenridge Pharmaceutical, Inc. (BPI), has filed an Abbreviated New Drug Application (ANDA) for Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets.

Both the entities’ Paragraph IV ANDA was filed on the First-to-File date and expected to be the only generic that is entitled to the 180-day exclusivity period.

Novartis AG sells Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets under Brand name Zortress in the USA market. Zortress is used to prevent organ rejection after a kidney or liver transplant. Zortress generated sales of $43.5 million for the twelve-month period ending July 2014, based on industry sales data.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

895.90 -12.20 (-1.34%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×